✦ LIBER ✦

PCN5 PHARMACOECONOMIC ANALYSIS OF SORAFENIB AND SUNITINIB FOR FIRST LINE TREATMENT OF METASTATIC RENAL CELL CARCINOMA (MRCC) COMPARED WITH COMBINATION THERAPY OF BEVACIZUMAB, GEMCITABINE, AND CAPECITABINE (BGC) AT A LARGE CANCER CENTER

✍ Scribed by WD Smith; R Arbuckle

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PCN17 COST OF MANAGING SIDE EFFECTS OF F

✍ GH Mickisch; B Escudier; M Gore; G Procopio; S Walzer; MJ Nuijten 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 92 KB

PCN42 COSTS OF MANAGING ADVERSE EVENTS O

✍ F Carlos; J Ramirez; A Aguirre 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 99 KB